Moreover, the 36-month beta value for CMMB is 0.63. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CMMB is 16.57M and currently, short sellers hold a 0.67% of that float. On January 01, 2025, CMMB’s average trading volume was 119.82K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CMMB) stock’s latest price update
Chemomab Therapeutics Ltd ADR (NASDAQ: CMMB)’s stock price has gone decline by -10.40 in comparison to its previous close of 2.02, however, the company has experienced a 9.70% increase in its stock price over the last five trading days. globenewswire.com reported 2024-12-03 that —Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companies with “Key, Near-Term, Potentially Stock-Moving Catalysts”— TEL AVIV, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it will participate in Oppenheimer’s Movers in Rare Disease Summit on Thursday, December 12, 2024, at the Westin Grand Central in New York City.
CMMB’s Market Performance
Chemomab Therapeutics Ltd ADR (CMMB) has experienced a 9.70% rise in stock performance for the past week, with a -0.55% drop in the past month, and a 20.67% rise in the past quarter. The volatility ratio for the week is 12.71%, and the volatility levels for the past 30 days are at 8.58% for CMMB. The simple moving average for the past 20 days is 4.74% for CMMB’s stock, with a 43.55% simple moving average for the past 200 days.
Analysts’ Opinion of CMMB
Many brokerage firms have already submitted their reports for CMMB stocks, with Maxim Group repeating the rating for CMMB by listing it as a “Buy.” The predicted price for CMMB in the upcoming period, according to Maxim Group is $4 based on the research report published on May 13, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CMMB reach a price target of $6. The rating they have provided for CMMB stocks is “Outperform” according to the report published on May 06th, 2024.
ROTH MKM gave a rating of “Buy” to CMMB, setting the target price at $7 in the report published on December 19th of the previous year.
CMMB Trading at 10.38% from the 50-Day Moving Average
After a stumble in the market that brought CMMB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.02% of loss for the given period.
Volatility was left at 8.58%, however, over the last 30 days, the volatility rate increased by 12.71%, as shares surge +1.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.29% upper at present.
During the last 5 trading sessions, CMMB rose by +9.70%, which changed the moving average for the period of 200-days by +126.45% in comparison to the 20-day moving average, which settled at $1.73. In addition, Chemomab Therapeutics Ltd ADR saw 254.90% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CMMB starting from OrbiMed Israel Partners Limite, who proposed sale 500,000 shares at the price of $2.03 back on Sep 12 ’24. After this action, OrbiMed Israel Partners Limite now owns shares of Chemomab Therapeutics Ltd ADR, valued at $1,015,000 using the latest closing price.
Stock Fundamentals for CMMB
The total capital return value is set at -0.93. Equity return is now at value -84.26, with -65.33 for asset returns.
Currently, EBITDA for the company is -25.39 million with net debt to EBITDA at 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.57.
Conclusion
To wrap up, the performance of Chemomab Therapeutics Ltd ADR (CMMB) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
